117 related articles for article (PubMed ID: 21095037)
1. Premature senescence induced by DNA demethylating agent (Decitabine) as therapeutic option for malignant pleural mesothelioma.
Amatori S; Bagaloni I; Viti D; Fanelli M
Lung Cancer; 2011 Jan; 71(1):113-5. PubMed ID: 21095037
[TBL] [Abstract][Full Text] [Related]
2. Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells.
Amatori S; Papalini F; Lazzarini R; Donati B; Bagaloni I; Rippo MR; Procopio A; Pelicci PG; Catalano A; Fanelli M
Lung Cancer; 2009 Nov; 66(2):184-90. PubMed ID: 19233506
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura.
Schrump DS; Fischette MR; Nguyen DM; Zhao M; Li X; Kunst TF; Hancox A; Hong JA; Chen GA; Pishchik V; Figg WD; Murgo AJ; Steinberg SM
Clin Cancer Res; 2006 Oct; 12(19):5777-85. PubMed ID: 17020984
[TBL] [Abstract][Full Text] [Related]
4. A 5-aza-2'-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma.
Leclercq S; Gueugnon F; Boutin B; Guillot F; Blanquart C; Rogel A; Padieu M; Pouliquen D; Fonteneau JF; Grégoire M
Eur Respir J; 2011 Nov; 38(5):1105-16. PubMed ID: 21540307
[TBL] [Abstract][Full Text] [Related]
5. Decitabine--bedside to bench.
Oki Y; Aoki E; Issa JP
Crit Rev Oncol Hematol; 2007 Feb; 61(2):140-52. PubMed ID: 17023173
[TBL] [Abstract][Full Text] [Related]
6. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition.
Choi SH; Byun HM; Kwan JM; Issa JP; Yang AS
Br J Haematol; 2007 Sep; 138(5):616-23. PubMed ID: 17686055
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
Hackanson B; Robbel C; Wijermans P; Lübbert M
Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
[TBL] [Abstract][Full Text] [Related]
8. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
[TBL] [Abstract][Full Text] [Related]
9. Response to the methylation inhibitor dihydro-5-azacytidine in mesothelioma is not associated with methylation of p16INK4a: results of cancer and leukemia group B 159904.
Kratzke RA; Wang X; Wong L; Kratzke MG; Green MR; Vokes EE; Vogelzang NJ; Kindler HL; Kern JA;
J Thorac Oncol; 2008 Apr; 3(4):417-21. PubMed ID: 18379362
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.
Takenouchi M; Hirai S; Sakuragi N; Yagita H; Hamada H; Kato K
Clin Cancer Res; 2011 May; 17(9):2819-29. PubMed ID: 21357681
[TBL] [Abstract][Full Text] [Related]
12. Taurolidine and povidone-iodine induce different types of cell death in malignant pleural mesothelioma.
Opitz I; Sigrist B; Hillinger S; Lardinois D; Stahel R; Weder W; Hopkins-Donaldson S
Lung Cancer; 2007 Jun; 56(3):327-36. PubMed ID: 17383050
[TBL] [Abstract][Full Text] [Related]
13. Advances in the systemic therapy of malignant pleural mesothelioma.
Fennell DA; Gaudino G; O'Byrne KJ; Mutti L; van Meerbeeck J
Nat Clin Pract Oncol; 2008 Mar; 5(3):136-47. PubMed ID: 18227828
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
[TBL] [Abstract][Full Text] [Related]
15. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: insight into EGFR and ERK1/2 as antitumor targets.
Barbieri F; Würth R; Favoni RE; Pattarozzi A; Gatti M; Ratto A; Ferrari A; Bajetto A; Florio T
Biochem Pharmacol; 2011 Nov; 82(10):1467-77. PubMed ID: 21787763
[TBL] [Abstract][Full Text] [Related]
16. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
[TBL] [Abstract][Full Text] [Related]
17. Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells.
Liu QY; Chen DW; Xie LP; Zhang RQ; Wang HZ
Environ Toxicol Pharmacol; 2011 Nov; 32(3):423-9. PubMed ID: 22004962
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for the therapy of leukemia.
Momparler RL; Côté S; Eliopoulos N
Leukemia; 1997 Mar; 11 Suppl 1():S1-6. PubMed ID: 9130684
[TBL] [Abstract][Full Text] [Related]
19. The role of Alimta in the treatment of malignant pleural mesothelioma: an overview of preclinical and clinical trials.
Hanauske AR
Lung Cancer; 2004 Aug; 45 Suppl 1():S121-4. PubMed ID: 15261444
[TBL] [Abstract][Full Text] [Related]
20. In vitro-chemosensitivity test using the collagen gel droplet embedded culture drug test (CD-DST) for malignant pleural mesothelioma: possibility of clinical application.
Higashiyama M; Oda K; Okami J; Maeda J; Kodama K; Takami K; Morinaga K; Takano T; Kobayashi H
Ann Thorac Cardiovasc Surg; 2008 Dec; 14(6):355-62. PubMed ID: 19131921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]